Fig. 3From: Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trialChanges of HBV virologic markers from baseline during treatment with Canocapavir or placebo. A–C Hepatitis B virus (HBV) DNA, D–F HBV pregenomic RNA (pgRNA), G hepatitis B surface antigen (HBsAg), H hepatitis e surface antigen (HBeAg), I hepatitis B core-related antigen (HBcrAg)Back to article page